A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Not Recruiting

Trial ID: NCT01677390

Purpose

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Official Title

A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Eligibility


Inclusion Criteria:

   - Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression

   - Previously treated with at least 1 tyrosine kinase inhibitor (TKI)

   - Measurable disease

   - Eastern Cooperative Oncology Group performance status 0 or 1

   - Adequate lung and renal function

Exclusion Criteria:

   - Prior treatment with anti-CD70-directed therapy

   - Received more than one prior treatment with an mTOR inhibitor

Intervention(s):

drug: SGN-75

drug: everolimus

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.